Article Impact Level: HIGH Data Quality: STRONG Summary of Annals of Internal Medicine https://doi.org/10.7326/ANNALS-25-00478 Dr. John A. Batsis et al.
Points
- Researchers conducted a systematic review which found that two-thirds of incretin-based weight loss interventions resulted in muscle loss that significantly exceeded established clinical benchmarks for healthy weight reduction.
- The study revealed that medications like semaglutide and tirzepatide are associated with a consistently higher proportion of fat-free mass loss compared to traditional nonpharmacologic lifestyle and diet interventions.
- Clinical experts express concern that current research lacks sufficient data on adults over sixty-five years who may face a higher risk of falls and decreased mobility from muscle depletion.
- The team advises clinicians to implement regular muscle health evaluations and functional measurements for any patients currently prescribed these widely used medications for managing obesity and type two diabetes.
- Future clinical trials must prioritize aging-related outcomes and investigate the biological mechanisms that drive disproportionate skeletal muscle loss to ensure patient safety and maintain overall quality of life.
Summary
This systematic review evaluated the impact of incretin-based therapies, including semaglutide and tirzepatide, on body composition relative to nonpharmacologic weight loss interventions. Given the rapid clinical adoption of GLP-1 and GIP receptor agonists for type 2 diabetes and obesity, the research sought to determine if the resulting weight reduction involves disproportionate losses in fat-free mass (FFM) and skeletal muscle. The study analyzed outcomes across various clinical trials to establish whether these pharmacologic agents accelerate sarcopenic shifts beyond expected physiological benchmarks.
The analysis revealed that loss of muscle-related indices exceeded prespecified benchmarks in two-thirds of incretin-based interventions. In comparison, only half of nonpharmacologic weight loss interventions surpassed these same thresholds. Investigators observed that while muscle loss is a characteristic feature of weight reduction, the magnitude of FFM attrition associated with incretin therapies was consistently higher than anticipated. Notably, the study highlighted a significant evidence gap concerning older populations, as very few trials included participants over 60 years and none specifically targeted adults aged 65 years or older.
The findings suggest that the clinical management of patients on incretin-based medications requires intensive monitoring of muscle health to mitigate risks such as impaired mobility and increased fall frequency. The researchers emphasize the necessity of integrating standardized muscle evaluations into future clinical trials to better understand the underlying mechanisms of disproportionate FFM loss. Because significant muscle depletion can compromise quality of life, particularly in geriatric populations, additional trials focused on aging-related functional outcomes are urgently required to ensure the long-term safety of these widely prescribed therapeutic agents.
Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-25-00478
References
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., Da Silva, B. R., Meira Filho, L. F., Jones, E. P., Batchek, D., Khandpekar, S., Patel, R., Awkal, B., Pape, A., Bahna, M., Zamboni, M., & Prado, C. M. (2026). Effect of incretin-based and nonpharmacologic weight loss on body composition: A systematic review. Annals of Internal Medicine, ANNALS-25-00478. https://doi.org/10.7326/ANNALS-25-00478
